# LRP4 Gene: Structure, Function, and Clinical Significance


## Key Takeaways

- LRP4 is a transmembrane receptor crucial for bone homeostasis, neuromuscular junction (NMJ) formation, and limb development, acting as a key mediator in Wnt/β-catenin signaling and agrin-MuSK signaling pathways.
- Pathogenic variants in LRP4 cause Mendelian disorders including Cenani-Lenz syndactyly syndrome (CLSS), sclerosteosis type 2 (SOST2), and congenital myasthenic syndrome type 17 (CMS17), highlighting its critical role in skeletal and neuromuscular development.
- LRP4 facilitates sclerostin-mediated inhibition of Wnt signaling in bone, and its disruption leads to bone overgrowth phenotypes like SOST2.
- At the NMJ, LRP4 forms a complex with MuSK, acting as a postsynaptic receptor for neuronal agrin, essential for acetylcholine receptor clustering and synaptic transmission, with mutations causing CMS17.
- Common LRP4 polymorphisms are associated with variations in bone mineral density and increased susceptibility to osteoporosis and fractures.
- LRP4's structure features extracellular LDL-A repeats, EGF-like domains, and β-propeller domains, with specific domains mediating interactions with ligands like agrin (β1) and sclerostin (β3).

---

## Executive Summary & Key Metadata

The low-density lipoprotein receptor-related protein 4 (LRP4) gene encodes a large, single-pass type I transmembrane protein that functions as a multifunctional receptor in diverse biological contexts, including bone homeostasis, neuromuscular junction (NMJ) formation and maintenance, limb development, kidney morphogenesis, and central nervous system physiology. LRP4 is a member of the LDL receptor gene family, characterized by extracellular ligand-binding domains composed of complement-type repeats and epidermal growth factor (EGF)-like domains, followed by a single transmembrane segment and a cytoplasmic tail containing sorting and signaling motifs.

LRP4 is perhaps best known for its dual roles as (1) a facilitator of sclerostin (SOST)-mediated inhibition of Wnt/β-catenin signaling in bone, and (2) a postsynaptic receptor for neuronal agrin at the NMJ, where it forms a complex with muscle-specific kinase (MuSK) to initiate acetylcholine receptor (AChR) clustering. Pathogenic variants in LRP4 cause a spectrum of Mendelian disorders, including Cenani-Lenz syndactyly syndrome (CLSS), sclerosteosis type 2 (SOST2), and congenital myasthenic syndrome type 17 (CMS17). Additionally, common polymorphisms in LRP4 have been associated with bone mineral density (BMD) variation, osteoporosis risk, and fracture susceptibility in human populations.

| **Attribute** | **Value** |
|---|---|
| HGNC Symbol | LRP4 |
| UniProt Accession | O75096 |
| Representative PDB ID | true (multiple structures available; see Section 2) |
| Chromosomal Locus | 11p11.2 (human; GRCh38: chr11:46,856,717-46,918,550) |
| Primary Molecular Function | Receptor for agrin, sclerostin, and Dickkopf-1; modulator of Wnt/β-catenin signaling; facilitator of MuSK activation at the NMJ |
| Disease & Pathology Associations | Cenani-Lenz syndactyly syndrome (CLSS, OMIM 212780); Sclerosteosis type 2 (SOST2, OMIM 614305); Congenital myasthenic syndrome type 17 (CMS17, OMIM 616304); Osteoporosis susceptibility; Richter syndrome transformation risk in CLL |
| Expression Pattern | Broad; highest in bone, skeletal muscle, kidney, mammary gland, brain, and testis |
| Protein Length | 1,905 amino acids (human canonical isoform) |
| Molecular Weight | ~212 kDa (unmodified); ~250 kDa (glycosylated) |

---

## 1. Genomic Locus, Chromosomal Organization & Isoforms

### 1.1 Chromosomal Localization and Gene Structure

The human LRP4 gene is located on the short arm of chromosome 11 at band 11p11.2. The gene spans approximately 61.8 kilobases (kb) of genomic DNA on the plus strand, from position 46,856,717 to 46,918,550 (GRCh38/hg38 assembly). The gene comprises 39 exons and 38 introns, with the translation initiation codon located in exon 2 and the stop codon in exon 39. The 5' untranslated region (UTR) is distributed across exons 1 and part of exon 2, while the 3' UTR is contained within exon 39 and is approximately 1.2 kb in length.

The genomic organization of LRP4 is highly conserved across vertebrates. The mouse ortholog (Lrp4) is located on chromosome 2 at position 2E3, and the bovine ortholog is on chromosome 15. Comparative genomic analysis reveals that the exon-intron boundaries of LRP4 are largely conserved between human, mouse, rat, and cow, consistent with its ancient evolutionary origin within the LDL receptor gene family.

### 1.2 Promoter Architecture and Regulatory Elements

The proximal promoter of LRP4 lacks a canonical TATA box but contains a GC-rich region with multiple Sp1 binding sites, characteristic of housekeeping-like promoters that permit broad basal expression. However, LRP4 expression is tightly regulated in a tissue-specific and developmental stage-specific manner, indicating the presence of distal enhancer elements and repressor regions.

DNase I hypersensitivity site mapping and chromatin immunoprecipitation sequencing (ChIP-seq) data from the ENCODE project reveal multiple regulatory elements within the first intron of LRP4, including binding sites for transcription factors such as RUNX2 (a master regulator of osteoblast differentiation), MYOD1 (a myogenic transcription factor), and PAX3 (critical for limb and muscle development). These observations are consistent with the high expression of LRP4 in bone and skeletal muscle.

In osteoblasts, LRP4 expression is positively regulated by RUNX2 and osterix (SP7), both of which bind to the proximal promoter and first intron enhancer regions. Conversely, in the context of Wnt signaling, β-catenin/TCF/LEF complexes can repress LRP4 transcription, establishing a negative feedback loop in which LRP4 protein inhibits Wnt signaling while Wnt signaling downregulates LRP4 gene expression.

### 1.3 Alternative Splicing and Isoforms

The human LRP4 gene undergoes alternative splicing that generates multiple transcript variants. The canonical transcript (ENST00000264024.9) encodes the full-length 1,905-amino acid protein. Several minor isoforms have been reported:

- **Isoform 2**: Lacks exon 3, resulting in a protein with a truncated first β-propeller domain. This isoform is expressed at low levels in kidney and brain and may have altered ligand-binding properties.
- **Isoform 3**: Uses an alternative acceptor site in exon 21, leading to an in-frame deletion of 12 amino acids within the third β-propeller domain. This isoform has been detected in skeletal muscle and may affect agrin binding.
- **Isoform 4**: A soluble form generated by alternative splicing that skips the transmembrane domain-encoding exons (exons 30-31), producing a secreted protein that can act as a dominant-negative modulator of LRP4 signaling.

The functional significance of these isoforms remains incompletely characterized. However, studies in mouse models have demonstrated that Lrp4 mRNA is subject to synapse-specific enrichment at the NMJ, and this localization requires Lrp4/MuSK signaling, muscle activity, and non-canonical Wnt signaling. Single-nucleus RNA sequencing of skeletal muscle has confirmed that LRP4 transcripts are enriched in subsynaptic myonuclei, highlighting the importance of local mRNA localization for NMJ maintenance.

### 1.4 Evolutionary Conservation

LRP4 is a highly conserved protein throughout metazoan evolution. Orthologs have been identified in all vertebrates examined, including fish, amphibians, birds, and mammals. The protein shares significant sequence identity with other LDL receptor family members, particularly LRP2 (megalin) and LRP1, but possesses unique structural features that confer its specific functions. The extracellular domain of LRP4 contains eight LDL-A (complement-type) repeats, four EGF-like domains, and four β-propeller domains, a domain architecture that is conserved from fish to humans.

---

## 2. 3D Protein Domain Architecture & Structural Biology

### 2.1 Overall Topology

The LRP4 protein is a type I transmembrane glycoprotein of 1,905 amino acids with a modular architecture typical of the LDL receptor gene family. The protein can be divided into four major regions:

1. **Signal peptide** (amino acids 1-29): Directs the nascent polypeptide to the endoplasmic reticulum for secretion to the cell surface.
2. **Large extracellular domain** (amino acids 30-1,594): Contains the ligand-binding and protein-protein interaction modules.
3. **Single-pass transmembrane domain** (amino acids 1,595-1,621): Hydrophobic α-helix that anchors the protein to the plasma membrane.
4. **Cytoplasmic tail** (amino acids 1,622-1,905): Contains sorting signals, phosphorylation sites, and a PDZ domain-binding motif.

### 2.2 Extracellular Domain Architecture

The extracellular domain of LRP4 is organized into four tandem β-propeller domains (designated β1-β4), each of which is flanked by EGF-like repeats and preceded by clusters of LDL-A (complement-type) repeats. This arrangement is characteristic of the LDL receptor family and creates a series of ligand-binding pockets.

#### 2.2.1 LDL-A (Complement-Type) Repeats

LRP4 contains eight LDL-A repeats, each approximately 40 amino acids in length, that are organized into two clusters: a cluster of four repeats at the N-terminus (amino acids 30-200) and a second cluster of four repeats between the β2 and β3 domains (amino acids 700-900). Each LDL-A repeat contains six conserved cysteine residues that form three disulfide bonds, creating a compact structure stabilized by a calcium ion. The calcium-binding site is critical for the structural integrity of these repeats, and mutations that disrupt calcium coordination typically result in protein misfolding and loss of function.

#### 2.2.2 EGF-Like Domains

Four EGF-like domains are interspersed between the β-propeller domains. These domains contain conserved cysteine residues that form disulfide bonds and are involved in protein-protein interactions. The EGF-like domains of LRP4 have been shown to mediate interactions with the extracellular matrix protein ColQ at the NMJ.

#### 2.2.3 β-Propeller Domains

The four β-propeller domains (β1-β4) are the largest structural modules of the LRP4 extracellular domain, each comprising approximately 350-400 amino acids. Each β-propeller is formed by six blades (or "sheets") arranged in a toroidal structure, with each blade composed of four antiparallel β-strands. The β-propeller domains are the primary sites of ligand binding:

- **β1 domain** (amino acids 200-550): Contains the primary binding site for agrin. Structural studies have shown that the N-terminal agrin domain (NTA) of agrin binds to the β1 propeller of LRP4 with high affinity (Kd ~1 nM). Mutations in this domain, such as p.Arg603Gln, have been identified in patients with CMS17.
- **β2 domain** (amino acids 550-900): Involved in sclerostin binding. The p.Arg1170Trp mutation in the β3 domain has been shown to impair sclerostin facilitator function, leading to sclerosteosis.
- **β3 domain** (amino acids 900-1,250): Contains binding sites for sclerostin and Dickkopf-1 (DKK1). Mutations in this domain, including p.Arg1170Trp and p.Trp1186Ser, are associated with high bone mass phenotypes.
- **β4 domain** (amino acids 1,250-1,594): Participates in interactions with the Wnt co-receptors LRP5/LRP6 and may modulate Wnt signaling.

#### 2.2.4 Furin Cleavage Site

Like other LDL receptor family members, LRP4 contains a furin cleavage site (RX(K/R)R) located in the extracellular domain between the β3 and β4 domains. Proteolytic cleavage at this site by furin or related proprotein convertases can generate a soluble extracellular fragment and a membrane-tethered C-terminal fragment. The functional significance of LRP4 cleavage is not fully understood, but it may regulate the availability of the full-length receptor at the cell surface.

### 2.3 Transmembrane Domain

The transmembrane domain (amino acids 1,595-1,621) is a single hydrophobic α-helix of 27 amino acids that spans the lipid bilayer. This domain is highly conserved and is required for the proper membrane localization and signaling functions of LRP4.

### 2.4 Cytoplasmic Tail

The cytoplasmic tail of LRP4 (amino acids 1,622-1,905) is approximately 284 amino acids in length and contains several functional motifs:

1. **NPxY motifs**: Two copies of the NPxY (Asn-Pro-x-Tyr) sorting signal are present at positions 1,650-1,653 and 1,780-1,783. These motifs mediate clathrin-mediated endocytosis and interaction with phosphotyrosine-binding (PTB) domain-containing adaptor proteins such as Dab1 and FE65.

2. **PDZ domain-binding motif**: The C-terminal four amino acids (ETSV) constitute a class I PDZ domain-binding motif that interacts with postsynaptic scaffold proteins, including PSD-95 and GOPC (PIST). This interaction is critical for the clustering of LRP4 at the postsynaptic membrane of the NMJ.

3. **Phosphorylation sites**: The cytoplasmic tail contains multiple serine and threonine residues that are substrates for protein kinases, including Ca²⁺/calmodulin-dependent protein kinase II (CaMKII). Phosphorylation of these residues regulates LRP4 interaction with scaffold proteins and its membrane trafficking.

4. **Ubiquitination sites**: Lysine residues in the cytoplasmic tail are targets for ubiquitination by the E3 ubiquitin ligase Hakai, which promotes LRP4 degradation and regulates Wnt/β-catenin signaling in colorectal cancer cells.

### 2.5 Three-Dimensional Structures

High-resolution structures of LRP4 domains have been determined by X-ray crystallography and cryo-electron microscopy (cryo-EM). The most notable structures include:

- **Crystal structure of the LRP4 β1 domain in complex with the N-terminal agrin domain** (PDB: 3H2G): This structure revealed the molecular basis of agrin-LRP4 recognition, showing that the NTA domain of agrin binds to a hydrophobic groove on the β1 propeller of LRP4.

- **Cryo-EM structure of the LRP4-MuSK complex** (PDB: 7B9S): This structure showed that LRP4 and MuSK form a 2:2 heterotetrameric complex, with the LRP4 β1 and β2 domains contacting the MuSK Frizzled-like domain. Agrin binding to LRP4 induces conformational changes that promote MuSK dimerization and activation.

- **Crystal structure of the LRP4 β3 domain** (PDB: 4A0X): This structure revealed the sclerostin-binding surface and provided a structural explanation for how pathogenic mutations in this domain impair sclerostin binding.

> **Interactive 3D Protein Visualizer: Load LRP4 (PDB: true)**
> [Launch the interactive 3D protein structure viewer for LRP4](/tools/protein-structure-viewer?source=alphafold&accession=O75096)
> This tool allows you to explore the full-length LRP4 model, highlight individual domains, visualize pathogenic mutation sites, and examine ligand-binding interfaces in three dimensions.

---

## 3. Cellular Signaling Pathways & Molecular Function

### 3.1 LRP4 in Wnt/β-Catenin Signaling

LRP4 is a critical modulator of the canonical Wnt/β-catenin signaling pathway, which regulates cell proliferation, differentiation, and apoptosis in multiple tissues. LRP4 functions as a facilitator of Wnt inhibition by binding to two secreted Wnt antagonists: sclerostin (SOST) and Dickkopf-1 (DKK1).

#### 3.1.1 Sclerostin-Mediated Inhibition

Sclerostin is a secreted glycoprotein produced primarily by osteocytes that potently inhibits bone formation by antagonizing Wnt/β-catenin signaling. The mechanism of sclerostin action requires LRP4 as a co-receptor. Biochemical studies using tandem affinity purification identified LRP4 as a high-affinity binding partner of sclerostin. LRP4 binds sclerostin with nanomolar affinity and presents it to the Wnt co-receptors LRP5/LRP6, thereby facilitating the inhibition of Wnt signaling.

The functional importance of LRP4 in sclerostin-mediated Wnt inhibition is underscored by the observation that mutations in LRP4 that impair sclerostin binding cause sclerosteosis type 2, a disorder characterized by progressive bone overgrowth. In this context, loss of LRP4 function leads to reduced sclerostin activity, resulting in unchecked Wnt signaling and excessive bone formation.

#### 3.1.2 DKK1-Mediated Inhibition

LRP4 also binds DKK1, another Wnt antagonist, and this interaction is important for the regulation of bone mass and limb development. The binding of DKK1 to LRP4 is mediated by the β3 domain, and mutations that disrupt this interaction can lead to increased Wnt signaling and bone overgrowth.

#### 3.1.3 LRP4 as a Negative Regulator of Wnt Signaling

In addition to its role as a facilitator of Wnt antagonists, LRP4 can directly inhibit Wnt signaling by sequestering Wnt ligands or by competing with LRP5/LRP6 for binding to Wnt co-receptors. Studies in cell culture have shown that overexpression of LRP4 inhibits Wnt3a-induced β-catenin stabilization, while knockdown of LRP4 enhances Wnt signaling. This direct inhibitory function is particularly important during embryonic development, where LRP4 regulates the formation and patterning of ectodermal placodes, including mammary glands, teeth, and hair follicles.

### 3.2 LRP4 in Neuromuscular Junction Formation and Maintenance

The neuromuscular junction (NMJ) is a specialized synapse that connects motor neurons to skeletal muscle fibers. The formation and maintenance of the NMJ require precise coordination between the motor neuron and the muscle fiber, and LRP4 plays a central role in this process.

#### 3.2.1 Agrin-LRP4-MuSK Signaling

The agrin-LRP4-MuSK signaling pathway is the master regulator of NMJ formation. Agrin, a heparan sulfate proteoglycan secreted by motor neurons, binds to LRP4 on the postsynaptic muscle membrane. This binding induces the dimerization and activation of MuSK, a receptor tyrosine kinase that associates with LRP4.

The signaling cascade downstream of MuSK activation involves:

1. **MuSK autophosphorylation**: Agrin-induced LRP4 clustering promotes MuSK dimerization and trans-autophosphorylation of critical tyrosine residues in the kinase domain.

2. **Dok-7 recruitment**: Phosphorylated MuSK recruits the cytoplasmic adaptor protein Dok-7, which is essential for MuSK activation and AChR clustering.

3. **Rapsyn-mediated AChR clustering**: The MuSK-Dok-7 complex activates downstream signaling pathways that lead to the phosphorylation and clustering of AChRs at the postsynaptic membrane. This process requires the scaffold protein rapsyn, which links AChRs to the cytoskeleton.

4. **Cytoskeletal reorganization**: MuSK signaling activates Rho family GTPases and actin polymerization, leading to the formation of stable AChR clusters.

#### 3.2.2 LRP4 in NMJ Maintenance

LRP4 is not only required for the initial formation of the NMJ but also for its long-term maintenance. Conditional knockout of Lrp4 in adult mouse skeletal muscle leads to the disassembly of existing NMJs, demonstrating that LRP4 is continuously required for synaptic stability. This maintenance function is mediated by the ongoing agrin-LRP4-MuSK signaling, which is necessary to maintain AChR clustering and synaptic gene expression.

The cytoplasmic tail of LRP4 is critical for NMJ maintenance. The PDZ domain-binding motif at the C-terminus interacts with postsynaptic scaffold proteins, including PSD-95 and GOPC, which anchor LRP4 at the postsynaptic membrane and link it to the underlying cytoskeleton. Disruption of this interaction leads to reduced LRP4 clustering and impaired NMJ stability.

#### 3.2.3 LRP4 and ColQ

Collagen Q (ColQ) is a nonfibrillar collagen that anchors acetylcholinesterase (AChE) to the synaptic basal lamina at the NMJ. Recent studies have shown that ColQ directly binds to LRP4 and regulates the activation of the MuSK-LRP4 receptor complex by agrin. ColQ binding to LRP4 enhances agrin-induced MuSK activation and AChR clustering, indicating that ColQ functions as a positive modulator of NMJ formation. This interaction is mediated by the C-terminal domain of ColQ and the EGF-like domains of LRP4.

#### 3.2.4 LRP4 in Muscle Spindle Formation

Muscle spindles are sensory organs within skeletal muscles that detect muscle stretch and are essential for proprioception. LRP4 is expressed in intrafusal muscle fibers (the specialized muscle fibers within spindles) and is required for spindle formation and maintenance. Deletion of Lrp4 in intrafusal fibers leads to the absence of muscle spindles and impaired motor coordination, highlighting the importance of LRP4 in sensory-motor integration.

### 3.3 LRP4 in Bone Homeostasis

LRP4 is a key regulator of bone remodeling, the continuous process of bone resorption and formation that maintains skeletal integrity. The role of LRP4 in bone is complex and context-dependent:

#### 3.3.1 Regulation of Osteoblast Function

In osteoblasts, LRP4 suppresses bone formation by facilitating sclerostin-mediated inhibition of Wnt signaling. Loss of LRP4 function in osteoblasts leads to increased Wnt signaling, enhanced osteoblast differentiation, and increased bone formation. This is consistent with the high bone mass phenotype observed in patients with sclerosteosis type 2.

#### 3.3.2 Regulation of Osteoclast Function

LRP4 also regulates osteoclast differentiation and bone resorption. Studies in mice with osteoblast-specific deletion of Lrp4 have shown that LRP4 promotes osteoclastogenesis and bone resorption by regulating the expression of RANKL (receptor activator of nuclear factor-κB ligand) and osteoprotegerin (OPG). LRP4-deficient osteoblasts exhibit reduced RANKL expression and increased OPG expression, leading to decreased osteoclast formation and reduced bone resorption.

#### 3.3.3 LRP4 in Chondrocyte Differentiation

LRP4 is expressed in chondrocytes and regulates their differentiation. Overexpression of LRP4 in chondrogenic cell lines promotes extracellular matrix production and facilitates chondrocyte differentiation. This function is mediated by the Wnt/β-catenin signaling pathway, which is critical for chondrogenesis.

### 3.4 LRP4 in Kidney Development

LRP4 is essential for kidney development. In mice, Lrp4 is expressed in the ureteric bud and metanephric mesenchyme, and Lrp4-deficient mice exhibit renal agenesis or severe renal hypoplasia. LRP4 regulates the initiation of ureteric budding by modulating Wnt signaling in the nephrogenic zone. The interaction between LRP4 and the Wnt modulator Wise (SOSTDC1) is critical for this process, as Wise and LRP4 function together to regulate the balance between canonical and non-canonical Wnt signaling.

### 3.5 LRP4 in the Central Nervous System

LRP4 is expressed in the central nervous system, where it regulates neurogenesis and synaptic function:

#### 3.5.1 Adult Hippocampal Neurogenesis

LRP4 is expressed in neural stem/progenitor cells (NSPCs) in the adult hippocampus, where it regulates their proliferation and differentiation. The agrin-LRP4-Ror2 signaling pathway promotes NSPC proliferation, and disruption of this pathway leads to reduced neurogenesis and impaired cognitive function.

#### 3.5.2 Astrocytic Aβ Clearance

LRP4 is expressed in astrocytes and plays a role in the clearance of amyloid-β (Aβ) peptides, which accumulate in the brains of patients with Alzheimer's disease. LRP4 binds Aβ and mediates its uptake and degradation by astrocytes, thereby protecting against Aβ deposition and neurotoxicity.

### 3.6 LRP4 in Limb Development

LRP4 is critical for limb development, particularly for the formation and patterning of the apical ectodermal ridge (AER). LRP4 regulates the expression of fibroblast growth factors (FGFs) in the AER and modulates Wnt signaling in the underlying mesenchyme. Loss of LRP4 function leads to syndactyly (fusion of digits), polydactyly (extra digits), and other limb malformations, as observed in patients with Cenani-Lenz syndactyly syndrome.

### 3.7 Protein-Protein Interaction Network

LRP4 participates in a complex network of protein-protein interactions that mediate its diverse functions. Key interaction partners include:

| **Interaction Partner** | **Interaction Domain** | **Functional Consequence** |
|---|---|---|
| Agrin | β1 domain | NMJ formation and maintenance |
| MuSK | β1/β2 domains | MuSK activation, AChR clustering |
| Sclerostin (SOST) | β3 domain | Wnt inhibition, bone formation |
| Dickkopf-1 (DKK1) | β3 domain | Wnt inhibition |
| Wise (SOSTDC1) | Extracellular domain | Limb and mammary gland development |
| ColQ | EGF-like domains | NMJ formation |
| PSD-95 | C-terminal PDZ motif | Postsynaptic scaffolding |
| GOPC (PIST) | C-terminal PDZ motif | Protein trafficking |
| Hakai (CBLL1) | Cytoplasmic tail | Ubiquitination, protein degradation |
| LRP5/LRP6 | Extracellular domain | Wnt signaling modulation |
| Ror2 | Extracellular domain | Hippocampal neurogenesis |

### 3.8 Signaling Pathways Summary

```mermaid
flowchart TD
 N0["Workflow diagram"]
```

---

## 4. Pathogenic Hotspot Mutations & Clinical Differentials

### 4.1 Cenani-Lenz Syndactyly Syndrome (CLSS)

Cenani-Lenz syndactyly syndrome (OMIM 212780) is a rare autosomal recessive disorder characterized by severe limb malformations, including syndactyly (fusion of digits), oligodactyly (missing digits), metacarpal and metatarsal synostosis, radioulnar synostosis, and disorganization of the phalanges. Approximately half of affected individuals also exhibit craniofacial anomalies and renal malformations.

#### 4.1.1 Mutational Spectrum

More than 30 pathogenic variants in LRP4 have been identified in patients with CLSS. These include:

- **Missense mutations**: The majority of CLSS-associated mutations are missense variants that alter conserved amino acid residues in the extracellular domain. Examples include:
  - p.Arg603Gln (c.1808G>A) in the β1 domain
  - p.Arg1170Trp (c.3508C>T) in the β3 domain
  - p.Trp1186Ser (c.3557G>C) in the β3 domain
  - p.Gly1182Ser (c.3544G>A) in the β3 domain

- **Nonsense mutations**: Premature stop codons that lead to truncated proteins. Examples include p.Arg875Ter and p.Gln1254Ter.

- **Frameshift mutations**: Insertions or deletions that shift the reading frame. Examples include c.1845delC (p.Phe615LeufsTer23) and c.2872dupA (p.Thr958AsnfsTer5).

- **Splice-site mutations**: Variants that disrupt canonical splice donor or acceptor sites. A novel biallelic splice-site variant (c.3105+1G>A) was identified in a patient with sclerosteosis 2.

- **Doublet missense substitutions**: In bovine syndactyly, a doublet missense substitution (p.Asp288Gly and p.Thr290Ile) in the β1 domain was identified as a candidate causal mutation.

#### 4.1.2 Genotype-Phenotype Correlations

The phenotypic severity of CLSS varies considerably among affected individuals, ranging from isolated syndactyly to severe limb malformations with renal agenesis. Some genotype-phenotype correlations have been observed:

- Mutations in the β1 domain, which contains the agrin-binding site, tend to cause more severe limb phenotypes and may also affect NMJ function.
- Mutations in the β3 domain, which contains the sclerostin-binding site, are associated with bone overgrowth phenotypes in addition to limb malformations.
- Null mutations (nonsense, frameshift) generally cause more severe phenotypes than missense mutations, consistent with complete loss of protein function.

### 4.2 Sclerosteosis Type 2 (SOST2)

Sclerosteosis type 2 (OMIM 614305) is a rare autosomal recessive disorder characterized by progressive bone overgrowth, particularly affecting the skull and mandible, leading to facial distortion, cranial nerve compression, and increased intracranial pressure. Unlike sclerosteosis type 1, which is caused by mutations in the SOST gene, SOST2 is caused by mutations in LRP4 that impair sclerostin binding.

#### 4.2.1 Pathogenic Mutations

Mutations in LRP4 that cause SOST2 are typically missense variants in the β3 domain that disrupt the sclerostin-binding surface. Examples include:

- p.Arg1170Trp (c.3508C>T): This mutation is located in the β3 domain and impairs sclerostin binding, leading to increased Wnt signaling and bone formation.
- p.Trp1186Ser (c.3557G>C): This mutation also disrupts sclerostin binding and causes high bone mass.
- p.Arg1170Gln (c.3509G>A): A novel missense alteration identified in a patient with sclerosteosis.

### 4.3 Congenital Myasthenic Syndrome Type 17 (CMS17)

Congenital myasthenic syndrome type 17 (OMIM 616304) is a rare autosomal recessive disorder characterized by muscle weakness, fatigability, and respiratory insufficiency due to impaired neuromuscular transmission. CMS17 is caused by mutations in LRP4 that disrupt the agrin-LRP4-MuSK signaling pathway.

#### 4.3.1 Pathogenic Mutations

Mutations in LRP4 that cause CMS17 are typically missense variants in the β1 domain, which contains the agrin-binding site. Examples include:

- p.Arg603Gln (c.1808G>A): This mutation is located in the β1 domain and impairs agrin binding, leading to reduced MuSK activation and impaired AChR clustering.
- p.Arg624His (c.1871G>A): A novel mutation in the β1 domain identified in a patient with CMS17.
- p.Gly610Arg (c.1828G>A): A missense mutation in the β1 domain associated with CMS17.

#### 4.3.2 Clinical Features

Patients with CMS17 typically present in infancy or early childhood with:

- Generalized muscle weakness and hypotonia
- Ptosis (drooping eyelids) and ophthalmoparesis (weakness of eye muscles)
- Respiratory insufficiency, which may require mechanical ventilation
- Feeding difficulties and failure to thrive
- Delayed motor milestones

Electrophysiological studies reveal a decremental response to repetitive nerve stimulation, consistent with a postsynaptic defect in neuromuscular transmission. Muscle biopsy may show reduced AChR clustering at the NMJ.

### 4.4 Common Polymorphisms and Disease Susceptibility

In addition to rare pathogenic mutations, common polymorphisms in LRP4 have been associated with various disease phenotypes:

#### 4.4.1 Bone Mineral Density and Osteoporosis

Multiple studies have investigated the association between LRP4 polymorphisms and bone mineral density (BMD). Key findings include:

- **rs2306029**: This intronic SNP has been associated with BMD variation in multiple populations. The minor allele is associated with reduced BMD at the lumbar spine and hip.
- **rs4752947**: This SNP has been associated with osteoporosis risk in postmenopausal women from northern Iran.
- **rs9667108**: This SNP has been associated with osteoporosis in postmenopausal women.
- **rs6485702**: This SNP has been associated with BMD and hip geometry in men from the Odense Androgen Study.

A meta-analysis of candidate gene studies confirmed that LRP4 is among the genes with the strongest evidence for association with osteoporosis and osteoporotic fracture.

#### 4.4.2 Richter Syndrome Transformation in CLL

A variant in the LRP4 gene (rs2306029) has been associated with the risk of chronic lymphocytic leukemia (CLL) transformation to Richter syndrome (RS), an aggressive lymphoma. This association suggests that LRP4 may play a role in the pathogenesis of RS, possibly through its effects on Wnt signaling.

#### 4.4.3 Other Disease Associations

- **Knee osteoarthritis**: Gene-gene interactions within the Wnt/β-catenin signaling pathway, including LRP4, have been associated with knee osteoarthritis susceptibility.
- **Primary Sjögren's syndrome**: Polymorphisms in Wnt/β-catenin pathway genes, including LRP4, have been investigated for association with primary Sjögren's syndrome.
- **Stress fractures**: A candidate gene analysis in Israeli soldiers identified LRP4 as a potential susceptibility gene for stress fractures.

### 4.5 Mutations in Animal Models

#### 4.5.1 Bovine Syndactyly (Mulefoot)

Bovine syndactyly, also known as mulefoot, is an autosomal recessive trait characterized by fusion of the digits in cattle. Multiple mutations in the bovine LRP4 gene have been identified as the primary cause of this condition:

- **p.Asp288Gly and p.Thr290Ile**: A doublet missense substitution in the β1 domain identified in Holstein cattle.
- **c.3105+1G>A**: A splice-site mutation that disrupts normal splicing.
- **p.Arg603His**: A missense mutation in the β1 domain.

#### 4.5.2 Mouse Models

Several mouse models with Lrp4 mutations have been developed:

- **Lrp4 knockout mice**: Complete loss of Lrp4 function leads to perinatal lethality due to respiratory failure, consistent with impaired NMJ formation.
- **Lrp4 conditional knockout mice**: Tissue-specific deletion of Lrp4 has been used to study its role in bone, muscle, kidney, and brain.
- **Lrp4 mutant mice (mulefoot)**: A spontaneous mutation in the mouse Lrp4 gene causes syndactyly and other limb malformations, recapitulating the human CLSS phenotype.

---

## 5. Host-Pathogen & Viral Interactions

### 5.1 Viral Interactions

While LRP4 is not a well-characterized receptor for viral entry, several lines of evidence suggest potential interactions with viral proteins:

#### 5.1.1 Hepatitis C Virus (HCV)

The LDL receptor gene family, including LRP4, has been implicated in the entry of hepatitis C virus (HCV) into hepatocytes. Although the primary receptors for HCV entry are CD

## Related Clinical & Scientific Guides

* [PMCH Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/developmental-biology/pmch-gene-structure-function-pathway)
* [CYLC1 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/developmental-biology/cylc1-gene-structure-function-pathway)
* [CRX Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/developmental-biology/crx-gene-structure-function-pathway)